Embecta Corp. $EMBC Shares Acquired by CWA Asset Management Group LLC

Key Points

• CWA Asset Management Group increased its Embecta holdings by 43.4% in the third quarter, bringing its stake to 537,838 shares valued at approximately $3.04 million. Institutional investors collectively own 93.83% of the company.
• Embecta insiders purchased 70,000 shares worth $334,200 during the last quarter, including 30,000 shares bought by CEO Devdatt Kurdikar and 20,000 shares acquired by Jeffrey Z. Mann.
• The company exceeded quarterly earnings expectations with EPS of $0.56 versus the $0.27 consensus and revenue of $271.7 million, though revenue declined 8.1% year over year. Analysts maintain a “Reduce” consensus rating with an average price target of $11.

CWA Asset Management Group LLC raised its holdings in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) by 43.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 537,838 shares of the company's stock after buying an additional 162,891 shares during the period. CWA Asset Management Group LLC owned about 0.95% of Embecta worth $3,044,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its position in Embecta by 138.4% in the first quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company's stock worth $9,184,000 after buying an additional 603,106 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Embecta by 7.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 934,210 shares of the company's stock valued at $8,258,000 after acquiring an additional 67,374 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Embecta by 1.3% in the 1st quarter. Bank of New York Mellon Corp now owns 823,787 shares of the company's stock worth $7,282,000 after purchasing an additional 10,468 shares during the period. Walleye Capital LLC acquired a new position in Embecta in the 1st quarter worth approximately $7,013,000. Finally, Rockefeller Capital Management L.P. boosted its stake in Embecta by 25.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 344,544 shares of the company's stock worth $4,093,000 after purchasing an additional 68,925 shares during the period. 93.83% of the stock is currently owned by institutional investors.

Insider Transactions at Embecta

In other news, CEO Devdatt Kurdikar purchased 30,000 shares of the business's stock in a transaction dated Wednesday, August 12th. The stock was bought at an average cost of $4.70 per share, with a total value of $141,000.00. Following the purchase, the chief executive officer directly owned 804,919 shares of the company's stock, valued at approximately $3,783,119.30. This trade represents a 3.87% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jeffrey Z. Mann purchased 20,000 shares of Embecta stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $4.99 per share, with a total value of $99,800.00. Following the completion of the acquisition, the insider owned 262,915 shares in the company, valued at $1,311,945.85. The trade was a 8.23% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 70,000 shares of company stock valued at $334,200. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on EMBC. Zacks Research upgraded shares of Embecta from a "strong sell" rating to a "hold" rating in a research report on Friday, July 17th. Weiss Ratings raised shares of Embecta from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, October 9th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $11.00.

Embecta Stock Up 3.4%

Embecta stock opened at $6.42 on Wednesday. Embecta Corp. has a 12 month low of $2.77 and a 12 month high of $14.91. The stock has a market cap of $363.76 million, a P/E ratio of 3.04 and a beta of 0.84. The company's fifty day simple moving average is $5.52 and its 200-day simple moving average is $4.99.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to analyst estimates of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%. Embecta's quarterly revenue was down 8.1% compared to the same quarter last year. During the same period last year, the company earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, equities research analysts expect that Embecta Corp. will post 1.84 earnings per share for the current fiscal year.

Embecta Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th were given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Thursday, August 27th. Embecta's dividend payout ratio is presently 2.70%.

Embecta Company Profile

Embecta Corporation NASDAQ: EMBC is a global diabetes-care company that develops, manufactures and markets medical devices used to deliver insulin and monitor blood glucose. Its product portfolio includes insulin pen needles, insulin syringes, safety-engineered injection devices, lancets and related diabetes-management products.

The company serves people with diabetes, health care professionals, hospitals and other health care providers through commercial operations and distribution partners in markets around the world.

Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.